Table 2.
Mutation status of endosalpingiotic lesions in women without ovarian low-grade serous tumour
| Endosalpingiosis |
|||
|---|---|---|---|
| Case ID | Site | Genotype | Other serous epithelial lesions (site) |
| NT-1 | Peritoneum | KRASG12D (MAF 37%) | Serous cystadenofibroma (ovary)* |
| NT-2 | Uterine serosa | WT | – |
| NT-3 | Lymph node | WT | – |
| NT-4 | Omentum | WT | Serous cystadenofibromas (ovary), LGSP (bladder) |
| NT-5 | Omentum | WT | Serous adenofibromas (ovary) |
| NT-6 | Lymph node | WT | – |
| NT-7 | Peritoneum | WT | – |
| NT-8 | Peritoneum | WT | – |
| NT-9 | Peritoneum | WT | – |
| NT-10 | Peritoneum | WT | – |
| NT-11 | Peritoneum | WT | – |
| NT-12 | Peritoneum (hernia sac) | WT | – |
| NT-13 | Ovary (inclusion cysts) | WT | – |
| Peritoneum | WT | – | |
| Omentum | WT | – | |
LGSP, low-grade serous proliferation, WT, wildtype.
*
KRASG12D is also present in the serous cystadenofibroma (MAF 21%).